Mutual Advisors LLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 5,172 shares of the company's stock, valued at approximately $444,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new stake in HealthEquity during the 4th quarter valued at approximately $10,304,089,000. T. Rowe Price Investment Management Inc. purchased a new stake in HealthEquity during the 4th quarter valued at approximately $78,107,000. Norges Bank bought a new position in shares of HealthEquity during the 4th quarter valued at approximately $74,701,000. Raymond James Financial Inc. bought a new position in shares of HealthEquity during the 4th quarter valued at approximately $45,728,000. Finally, Iron Triangle Partners LP bought a new position in shares of HealthEquity during the 4th quarter valued at approximately $32,202,000. 99.55% of the stock is owned by hedge funds and other institutional investors.
HealthEquity Trading Up 1.3%
HQY traded up $1.29 during trading on Tuesday, reaching $103.12. The company had a trading volume of 972,980 shares, compared to its average volume of 1,038,871. The stock has a market cap of $8.92 billion, a P/E ratio of 75.27, a PEG ratio of 1.57 and a beta of 0.49. The business has a 50 day simple moving average of $100.09 and a 200-day simple moving average of $98.36. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $116.65. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50.
HealthEquity (NASDAQ:HQY - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. The company had revenue of $330.80 million during the quarter, compared to the consensus estimate of $322.25 million. During the same period last year, the company earned $0.80 earnings per share. On average, equities analysts anticipate that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.
Insiders Place Their Bets
In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the sale, the director owned 84,969 shares in the company, valued at $6,597,842.85. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jon Kessler sold 97,767 shares of the stock in a transaction on Friday, June 6th. The stock was sold at an average price of $112.05, for a total value of $10,954,792.35. Following the completion of the sale, the director owned 75,000 shares in the company, valued at approximately $8,403,750. The trade was a 56.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,700 shares of company stock worth $32,968,990 over the last quarter. Company insiders own 1.50% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on HQY shares. Raymond James Financial reiterated a "strong-buy" rating and set a $120.00 target price (up from $115.00) on shares of HealthEquity in a research report on Tuesday. Wall Street Zen upgraded HealthEquity from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Bank of America increased their target price on HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. JMP Securities increased their target price on HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research report on Wednesday, June 4th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, HealthEquity currently has an average rating of "Buy" and a consensus price target of $118.55.
Read Our Latest Stock Report on HealthEquity
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
